Document Detail


Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children.
MedLine Citation:
PMID:  18000092     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: Although GH has been used to treat short stature in GH deficiency (GHD) and other conditions for more than 40 yr, criteria for satisfactorily defining targets for GH responsiveness have never been developed. OBJECTIVE: The objective of this study was to present the first-year growth expressed as height velocity (HV) for prepubertal boys and girls with idiopathic GHD, organic GHD, idiopathic short stature, or Turner syndrome from Genentech's National Cooperative Growth Study to derive age-specific targets for GH responsiveness for each etiology and gender. DESIGN AND POPULATION: Using data from the National Cooperative Growth Study, we constructed curves of response to GH during the first year of treatment with standard daily doses in naive-to-treatment prepubertal children with idiopathic GHD (2323 males, 842 females), organic GHD (582 males, 387 females), idiopathic short stature (1392 males, 465 females), or Turner syndrome (1367 females). MAIN OUTCOME MEASURE: For each category, mean pretreatment and mean +/-1 and +/-2 sd for the first-year HV on GH were assessed. Mean and mean +/- 1 sd for HV were plotted vs. age at baseline (initiation of GH treatment) and compared with mean pretreatment HV. RESULTS: HV plots for each category as a factor of age at baseline are presented. Mean - 2 sd HV plots approximated the pretreatment HV. CONCLUSION: Using baseline age- and gender-specific targets will assist clinicians in assessing a patient's first-year growth response. We propose that HV below the mean - 1 sd on these plots be considered a "poor" response. These curves may be used to identify patients who may benefit from GH dose adjustment, to assess compliance issues, or to challenge the original diagnosis.
Authors:
Bert Bakker; James Frane; Henry Anhalt; Barbara Lippe; Ron G Rosenfeld
Publication Detail:
Type:  Journal Article; Multicenter Study     Date:  2007-11-13
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  93     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-08     Completed Date:  2008-04-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  352-7     Citation Subset:  AIM; IM    
Affiliation:
Genentech, Inc., 1 DNA Way, mailstop 454 B, South San Francisco, California 94080, USA. bakker.bert@gene.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Body Height / drug effects*
Child
Child, Preschool
Cross-Sectional Studies
Dose-Response Relationship, Drug
Female
Growth Disorders / drug therapy*
Human Growth Hormone / deficiency,  therapeutic use*
Humans
Male
Recombinant Proteins / therapeutic use
Reference Values
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 12629-01-5/Human Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern...
Next Document:  Prediction model for adult height of small for gestational age children at the start of growth hormo...